Pharmafile Logo

UCB SA

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for UCB SA in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring UCB SA.

Recent articles on PMLiVE featuring UCB SA

- PMLiVE
UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE
UCB releases new data on Bimzelx for hidradenitis suppurativa

The disease affects around 1% of the population in most studied countries

- PMLiVE
UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

The study demonstrated a sustained reduction in seizures for patients

- PMLiVE
UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

- PMLiVE
UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE
2025 PM Society Awards – winners announced

21GRAMS and Havas Lynx win big; AstraZeneca and UCB top client leader board

- PMLiVE
UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE
UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

The drug showed benefits across key secondary endpoints, including tau accumulation

- PMLiVE
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa

The inflammatory skin disease affects about 1% of the population in most studied countries

- PMLiVE
NICE recommends Theramex’s Eladynos to treat bone disease after menopause

Osteoporosis, which particularly impacts older women after menopause, currently affects 3.8 million people in the UK

- PMLiVE
Collaborating for change in rheumatology

Elevating the standard of care through multistakeholder consensus

- PMLiVE
UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults

The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links